Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome

Cell Cycle

Volumn 8, Issue 20, 2009, Pages 3303-3306

  Zhuang, Zhengping ^a   Lu, Jie ^a   Lonser, Russell ^a   Kovach, John S ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Lixte Biotechnology Holdings Inc   (United States)

Author keywords

Cancer chemotherapy; Cell cycle modulation; DNA damage; Phospho proteome; PP2A

Indexed keywords

7 HYDROXYSTAUROSPORINE; AZD 2281; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CARBOPLATIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; ESTROGEN RECEPTOR; GEMCITABINE; LB 12; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PIFITHRIN ALPHA; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER STEM CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL KILLING; CELL PROTECTION; CELL SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; GENE MUTATION; GLIOBLASTOMA; HUMAN; MITOSIS; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK;

ANIMALIA;

EID: 70350228780     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.20.9689     Document Type: Review

References (37)

1. th ed. Churchill Livingstone 2008; 1-48.
2. Pardee AB, James LJ. Selective killing of transformed baby hamster kidney (BHK) cells. Proc Nat Acad Sci USA 1975; 72:4994-4998
3. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; doi 10.1016/j.cell.2009.02.024.823-37.
4. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8:547-559
5. Drucker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of BCR-ABL kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037 (Pubitemid 32267972)
6. Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, et al. Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009; prepublished online: blood-2009-01-197186v1.
7. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001; 61:4301-4305
8. Blagosklonny MV, Darzinkiewicz Z. Cyclotherapy Protection of normal cells and unshielding of cancer cell. Cell Cycle 2002; 1:375-382
9. Blagosklonny MV. "Targeting the absence" and therapeutic engineering for cancer therapy. Cell Cycle 2008; 7:1307-1312 (Pubitemid 351872564)
10. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004; 3:513-519
11. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 2008; 8:512-522
12. Peralta-Leal A, Rodriguez-Vargas JM, Aguilar-Quesada R, Rodriguez MI, Linares JL, de Almodovar RM, et al. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 2009; 47:13-26.
13. Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogen DA, et al. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 2008; 68:10034-10039
14. Ashwell S, Janetka JW, Zabludoff S. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs 2008; 17:1331-1340
15. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98:523-528 (Pubitemid 351214533)
16. Perez RP, Lewis LD, Beelen AP, Olszansky AJ, Johnston N, Rhodes CH, et al. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res 2006; 12:7079-7085 (Pubitemid 44974507)
17. Edelman MJ, Bauer KS Jr, Wu S, Smith R, Bisacia S, Dancey J. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res 2007; 13:2667-2674 (Pubitemid 46788034)
18. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, et al. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 2008; 61:423-433 (Pubitemid 350275977)
19. Iglehart JD, Silver DP. Synthetic lethality - a new direction in cancer-drug development. N Engl J Med 2009; 361:189-191
20. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-134
21. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009; 27:18.
22. Jaspers J, Rottenberg S, Jonkers J. Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochem Biophys Acta 2009; doi:10.1016/j.bbcan.2009.07.001.
23. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumor initiating cells. Nature 2004; 432:396-401. (Pubitemid 39551674)
24. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006; 66:1883-1890 (Pubitemid 43294892)
25. Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 2009; 7:989-999
26. Lu J, Kovach JS, Johnson F, Chiang L, Hodes R, Lonser R, Zhuang Z. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci USA 2009; 106:11697-11702
27. Westermark J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14:152-160
28. Castedo M, Perfettini JL, Roumier T, Andreau K, Medina R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23:2825-2837 (Pubitemid 38638845)
29. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008; 27:5511-5526
30. 2 and protects from tmomozolomide-induced mitotic catstrophe and cellular senescence. Cancer Res 2005; 65:4861-4869
31. Andrabi S, Gjoerup OV, Kean JA, Roberts TM, Schaffhausen. Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proc Natl Acad Sci USA 2007; 104:19011-19016
32. Yarm FR. Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol Cell Biol 2002; 22:6209-6221
33. Bommer UA, Thiele BJ. The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol 2004; 36:379-385
34. Chen SH, Wu PS, Chou CH, Yan YT, Liu H, Weng SY, Yang-Yen HF. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol Biol Cell 2007; 18:2525-2532 (Pubitemid 47025718)
35. Susini L, Besse S, Duflaut D, Laspagnol A, Beekman C, Fiucci G, et al. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ 2008; 15:1211-1220 (Pubitemid 351984751)
36. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 2009; Epub ahead of print; doi:10.1038/cdd.2009.68.
37. Thomson M, Gunawardena J. Unlimited multistability in multisite phosphorylation systems. Nature 2009; 460:274-277